ADEL Y07
Alternative Names: ADEL-Y07Latest Information Update: 16 Oct 2023
At a glance
- Originator ADEL
- Class Anti-inflammatories; Antineoplastics; Neuroprotectants
- Mechanism of Action Androgen receptor antagonists; Autophagy stimulants; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Inflammation; Neurodegenerative disorders; Prostate cancer
Most Recent Events
- 21 Sep 2023 ADEL Y07 is available for licensing as of 21 Sep 2023. https://www.adelpharm.com/adel-y07
- 21 Sep 2023 Early research in Cancer in South Korea (unspecified route), prior to September 2023 (ADEL pipeline, September 2023)
- 21 Sep 2023 Early research in Inflammation in South Korea (unspecified route), prior to September 2023 (ADEL pipeline, September 2023)